MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
Sonoma Pharmaceuticals Book Value 2011-2026 | SNOA
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.41 M | 6.14 M | 7.98 M | 8.7 M | 5.36 M | 8.7 M | 10.5 M | 15.3 M | 21.4 M | 10.1 M | 12.1 M | 12.1 M | 4.08 M | -868 K | 1.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.4 M | -868 K | 8.51 M |
Quarterly Book Value Sonoma Pharmaceuticals
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.43 M | 3.79 M | 4.06 M | 4.41 M | 4.87 M | 5.35 M | 4.98 M | 6.14 M | 6.69 M | 5.68 M | 7.24 M | 7.98 M | 5.56 M | 7.02 M | 7.96 M | 8.7 M | 11.2 M | 11.5 M | 4.62 M | 5.36 M | 12.3 M | 11.6 M | 10.7 M | 11.4 M | 11.2 M | 10.3 M | 11.5 M | 10.5 M | 13.3 M | 10.8 M | 12.6 M | 15.3 M | 14.3 M | 16.2 M | 18.6 M | 21.4 M | 22.9 M | 6.04 M | 7.75 M | 10.1 M | 9.12 M | 10.7 M | 11.1 M | 12.1 M | 7.83 M | 13.4 M | 13.4 M | 12.1 M | 3.4 M | 1.55 M | 2.62 M | 4.08 M | 3.13 M | -501 K | 342 K | -868 K | 163 K | -136 K | 387 K | 1.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 22.9 M | -868 K | 8.18 M |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
94 M | $ 18.02 | - | $ 115 M | USA |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 3.09 | -0.64 % | $ 43.4 M | USA |
 |
Cronos Group
CRON
|
1.71 B | $ 2.58 | 1.18 % | $ 1.34 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
-82 M | $ 5.6 | 3.9 % | $ 2.04 B | Canada |
 |
Harrow Health
HROW
|
52.1 M | $ 35.93 | -3.65 % | $ 1.32 B | USA |
 |
Aurora Cannabis
ACB
|
609 M | $ 3.43 | -1.44 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.05 | -3.67 % | $ 113 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
265 M | - | - | $ 193 M | Canada |
 |
Jupiter Wellness
JUPW
|
35 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-23.1 M | $ 4.27 | 0.71 % | $ 275 M | USA |
 |
Emergent BioSolutions
EBS
|
649 M | $ 7.96 | -5.8 % | $ 408 M | USA |
 |
Organogenesis Holdings
ORGO
|
385 M | $ 2.38 | 3.93 % | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
778 M | $ 23.79 | -0.13 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
1.1 B | $ 1.42 | 2.9 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
86.5 M | $ 7.29 | -4.2 % | $ 288 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 1.0 | 0.81 % | $ 49.9 M | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
180 M | $ 8.02 | -0.99 % | $ 702 M | USA |
 |
Tilray
TLRY
|
3.33 B | $ 6.57 | -2.23 % | $ 4.06 B | Canada |
 |
Veru
VERU
|
32.3 M | $ 2.38 | -2.06 % | $ 321 M | USA |
 |
Viatris
VTRS
|
21.1 B | $ 13.47 | -1.03 % | $ 16.2 B | USA |
 |
cbdMD
YCBD
|
1.96 M | $ 0.68 | 4.01 % | $ 2.93 M | USA |
 |
Zomedica Corp.
ZOM
|
115 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
37 M | $ 0.91 | -2.17 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
22.7 M | $ 0.63 | -3.82 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
26.9 M | $ 2.07 | 0.98 % | $ 23.9 M | USA |